Health Care·Pharmaceuticals·$119.9B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.48 | N/A | +7.62% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $0.48 | N/A | +7.62% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Overall, management expressed confidence in their product offerings and future growth potential. However, they did not provide specific guidance for the upcoming quarters.
Management highlighted the continued strength in their pipeline.
They emphasized a commitment to innovation and addressing unmet medical needs.
Bristol Myers Squibb's earnings report shows a positive surprise in EPS, which contributed to a slight increase in stock price. The management's optimistic tone regarding their pipeline suggests potential for future growth, although the lack of revenue data and guidance leaves some uncertainty. Investors may view the EPS beat as a sign of resilience in the company's performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
CANADIAN NATL RY CO
Jul 21, 2014